
Global Radionuclide Drug Conjugate(RDC) Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Radionuclide Drug Conjugate(RDC) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Radionuclide Drug Conjugate(RDC) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Radionuclide Drug Conjugate(RDC) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Radionuclide Drug Conjugate(RDC) market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Radionuclide Drug Conjugate(RDC) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Radionuclide Drug Conjugate(RDC) market include China Tongfang Pharmaceuticals, Zhihe Biotechnology, Yuanda Pharmaceuticals, Novartis, Kelun Biotech, Hengrui, Fulian Pharmaceuticals, Dongcheng Pharmaceuticals and Bayer, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Radionuclide Drug Conjugate(RDC), revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Radionuclide Drug Conjugate(RDC), also provides the value of main regions and countries. Of the upcoming market potential for Radionuclide Drug Conjugate(RDC), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Radionuclide Drug Conjugate(RDC) revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Radionuclide Drug Conjugate(RDC) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Radionuclide Drug Conjugate(RDC) company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Radionuclide Drug Conjugate(RDC) Segment by Company
China Tongfang Pharmaceuticals
Zhihe Biotechnology
Yuanda Pharmaceuticals
Novartis
Kelun Biotech
Hengrui
Fulian Pharmaceuticals
Dongcheng Pharmaceuticals
Bayer
Telix Pharmaceuticals
Lantheus
Curium
Radionuclide Drug Conjugate(RDC) Segment by Type
Therapy
Diagnosis
Radionuclide Drug Conjugate(RDC) Segment by Application
Prostate Cancer
Neuroendocrine Cancer
Other
Radionuclide Drug Conjugate(RDC) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Radionuclide Drug Conjugate(RDC) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Radionuclide Drug Conjugate(RDC) key companies, revenue, market share, and recent developments.
3. To split the Radionuclide Drug Conjugate(RDC) breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Radionuclide Drug Conjugate(RDC) market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Radionuclide Drug Conjugate(RDC) significant trends, drivers, influence factors in global and regions.
6. To analyze Radionuclide Drug Conjugate(RDC) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radionuclide Drug Conjugate(RDC) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radionuclide Drug Conjugate(RDC) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radionuclide Drug Conjugate(RDC).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Radionuclide Drug Conjugate(RDC) industry.
Chapter 3: Detailed analysis of Radionuclide Drug Conjugate(RDC) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Radionuclide Drug Conjugate(RDC) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Radionuclide Drug Conjugate(RDC) in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Radionuclide Drug Conjugate(RDC) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Radionuclide Drug Conjugate(RDC) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Radionuclide Drug Conjugate(RDC) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Radionuclide Drug Conjugate(RDC) market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Radionuclide Drug Conjugate(RDC) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Radionuclide Drug Conjugate(RDC) market include China Tongfang Pharmaceuticals, Zhihe Biotechnology, Yuanda Pharmaceuticals, Novartis, Kelun Biotech, Hengrui, Fulian Pharmaceuticals, Dongcheng Pharmaceuticals and Bayer, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Radionuclide Drug Conjugate(RDC), revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Radionuclide Drug Conjugate(RDC), also provides the value of main regions and countries. Of the upcoming market potential for Radionuclide Drug Conjugate(RDC), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Radionuclide Drug Conjugate(RDC) revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Radionuclide Drug Conjugate(RDC) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Radionuclide Drug Conjugate(RDC) company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Radionuclide Drug Conjugate(RDC) Segment by Company
China Tongfang Pharmaceuticals
Zhihe Biotechnology
Yuanda Pharmaceuticals
Novartis
Kelun Biotech
Hengrui
Fulian Pharmaceuticals
Dongcheng Pharmaceuticals
Bayer
Telix Pharmaceuticals
Lantheus
Curium
Radionuclide Drug Conjugate(RDC) Segment by Type
Therapy
Diagnosis
Radionuclide Drug Conjugate(RDC) Segment by Application
Prostate Cancer
Neuroendocrine Cancer
Other
Radionuclide Drug Conjugate(RDC) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Radionuclide Drug Conjugate(RDC) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Radionuclide Drug Conjugate(RDC) key companies, revenue, market share, and recent developments.
3. To split the Radionuclide Drug Conjugate(RDC) breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Radionuclide Drug Conjugate(RDC) market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Radionuclide Drug Conjugate(RDC) significant trends, drivers, influence factors in global and regions.
6. To analyze Radionuclide Drug Conjugate(RDC) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radionuclide Drug Conjugate(RDC) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radionuclide Drug Conjugate(RDC) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radionuclide Drug Conjugate(RDC).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Radionuclide Drug Conjugate(RDC) industry.
Chapter 3: Detailed analysis of Radionuclide Drug Conjugate(RDC) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Radionuclide Drug Conjugate(RDC) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Radionuclide Drug Conjugate(RDC) in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
197 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Radionuclide Drug Conjugate(RDC) Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Radionuclide Drug Conjugate(RDC) Market Size (2020-2031)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Radionuclide Drug Conjugate(RDC) Market Dynamics
- 2.1 Radionuclide Drug Conjugate(RDC) Industry Trends
- 2.2 Radionuclide Drug Conjugate(RDC) Industry Drivers
- 2.3 Radionuclide Drug Conjugate(RDC) Industry Opportunities and Challenges
- 2.4 Radionuclide Drug Conjugate(RDC) Industry Restraints
- 3 Radionuclide Drug Conjugate(RDC) Market by Company
- 3.1 Global Radionuclide Drug Conjugate(RDC) Company Revenue Ranking in 2024
- 3.2 Global Radionuclide Drug Conjugate(RDC) Revenue by Company (2020-2025)
- 3.3 Global Radionuclide Drug Conjugate(RDC) Company Ranking (2023-2025)
- 3.4 Global Radionuclide Drug Conjugate(RDC) Company Manufacturing Base and Headquarters
- 3.5 Global Radionuclide Drug Conjugate(RDC) Company Product Type and Application
- 3.6 Global Radionuclide Drug Conjugate(RDC) Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Radionuclide Drug Conjugate(RDC) Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.7.3 2024 Radionuclide Drug Conjugate(RDC) Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
- 4 Radionuclide Drug Conjugate(RDC) Market by Type
- 4.1 Radionuclide Drug Conjugate(RDC) Type Introduction
- 4.1.1 Therapy
- 4.1.2 Diagnosis
- 4.2 Global Radionuclide Drug Conjugate(RDC) Sales Value by Type
- 4.2.1 Global Radionuclide Drug Conjugate(RDC) Sales Value by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Radionuclide Drug Conjugate(RDC) Sales Value by Type (2020-2031)
- 4.2.3 Global Radionuclide Drug Conjugate(RDC) Sales Value Share by Type (2020-2031)
- 5 Radionuclide Drug Conjugate(RDC) Market by Application
- 5.1 Radionuclide Drug Conjugate(RDC) Application Introduction
- 5.1.1 Prostate Cancer
- 5.1.2 Neuroendocrine Cancer
- 5.1.3 Other
- 5.2 Global Radionuclide Drug Conjugate(RDC) Sales Value by Application
- 5.2.1 Global Radionuclide Drug Conjugate(RDC) Sales Value by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Radionuclide Drug Conjugate(RDC) Sales Value by Application (2020-2031)
- 5.2.3 Global Radionuclide Drug Conjugate(RDC) Sales Value Share by Application (2020-2031)
- 6 Radionuclide Drug Conjugate(RDC) Regional Value Analysis
- 6.1 Global Radionuclide Drug Conjugate(RDC) Sales Value by Region: 2020 VS 2024 VS 2031
- 6.2 Global Radionuclide Drug Conjugate(RDC) Sales Value by Region (2020-2031)
- 6.2.1 Global Radionuclide Drug Conjugate(RDC) Sales Value by Region: 2020-2025
- 6.2.2 Global Radionuclide Drug Conjugate(RDC) Sales Value by Region (2026-2031)
- 6.3 North America
- 6.3.1 North America Radionuclide Drug Conjugate(RDC) Sales Value (2020-2031)
- 6.3.2 North America Radionuclide Drug Conjugate(RDC) Sales Value Share by Country, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Radionuclide Drug Conjugate(RDC) Sales Value (2020-2031)
- 6.4.2 Europe Radionuclide Drug Conjugate(RDC) Sales Value Share by Country, 2024 VS 2031
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Radionuclide Drug Conjugate(RDC) Sales Value (2020-2031)
- 6.5.2 Asia-Pacific Radionuclide Drug Conjugate(RDC) Sales Value Share by Country, 2024 VS 2031
- 6.6 South America
- 6.6.1 South America Radionuclide Drug Conjugate(RDC) Sales Value (2020-2031)
- 6.6.2 South America Radionuclide Drug Conjugate(RDC) Sales Value Share by Country, 2024 VS 2031
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Radionuclide Drug Conjugate(RDC) Sales Value (2020-2031)
- 6.7.2 Middle East & Africa Radionuclide Drug Conjugate(RDC) Sales Value Share by Country, 2024 VS 2031
- 7 Radionuclide Drug Conjugate(RDC) Country-level Value Analysis
- 7.1 Global Radionuclide Drug Conjugate(RDC) Sales Value by Country: 2020 VS 2024 VS 2031
- 7.2 Global Radionuclide Drug Conjugate(RDC) Sales Value by Country (2020-2031)
- 7.2.1 Global Radionuclide Drug Conjugate(RDC) Sales Value by Country (2020-2025)
- 7.2.2 Global Radionuclide Drug Conjugate(RDC) Sales Value by Country (2026-2031)
- 7.3 USA
- 7.3.1 USA Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.3.2 USA Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.3.3 USA Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.4 Canada
- 7.4.1 Canada Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.4.2 Canada Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.4.3 Canada Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.5 Mexico
- 7.5.1 Mexico Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.5.2 Mexico Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.5.3 Mexico Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.6 Germany
- 7.6.1 Germany Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.6.2 Germany Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Germany Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.7 France
- 7.7.1 France Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.7.2 France Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.7.3 France Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.8 U.K.
- 7.8.1 U.K. Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.8.2 U.K. Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.8.3 U.K. Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.9 Italy
- 7.9.1 Italy Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.9.2 Italy Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.9.3 Italy Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.10 Spain
- 7.10.1 Spain Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.10.2 Spain Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.10.3 Spain Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.11 Russia
- 7.11.1 Russia Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.11.2 Russia Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Russia Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.12 Netherlands
- 7.12.1 Netherlands Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.12.2 Netherlands Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Netherlands Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.13.2 Nordic Countries Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Nordic Countries Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.14 China
- 7.14.1 China Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.14.2 China Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.14.3 China Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.15 Japan
- 7.15.1 Japan Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.15.2 Japan Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Japan Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.16 South Korea
- 7.16.1 South Korea Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.16.2 South Korea Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.16.3 South Korea Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.17 India
- 7.17.1 India Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.17.2 India Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.17.3 India Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.18 Australia
- 7.18.1 Australia Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.18.2 Australia Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.18.3 Australia Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.19.2 Southeast Asia Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.19.3 Southeast Asia Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.20 Brazil
- 7.20.1 Brazil Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.20.2 Brazil Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Brazil Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.21 Argentina
- 7.21.1 Argentina Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.21.2 Argentina Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Argentina Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.22 Chile
- 7.22.1 Chile Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.22.2 Chile Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Chile Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.23 Colombia
- 7.23.1 Colombia Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.23.2 Colombia Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Colombia Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.24 Peru
- 7.24.1 Peru Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.24.2 Peru Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Peru Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.25.2 Saudi Arabia Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Saudi Arabia Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.26 Israel
- 7.26.1 Israel Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.26.2 Israel Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Israel Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.27 UAE
- 7.27.1 UAE Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.27.2 UAE Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.27.3 UAE Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.28 Turkey
- 7.28.1 Turkey Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.28.2 Turkey Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Turkey Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.29 Iran
- 7.29.1 Iran Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.29.2 Iran Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.29.3 Iran Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 7.30 Egypt
- 7.30.1 Egypt Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2020-2031)
- 7.30.2 Egypt Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Egypt Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 China Tongfang Pharmaceuticals
- 8.1.1 China Tongfang Pharmaceuticals Comapny Information
- 8.1.2 China Tongfang Pharmaceuticals Business Overview
- 8.1.3 China Tongfang Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)
- 8.1.4 China Tongfang Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
- 8.1.5 China Tongfang Pharmaceuticals Recent Developments
- 8.2 Zhihe Biotechnology
- 8.2.1 Zhihe Biotechnology Comapny Information
- 8.2.2 Zhihe Biotechnology Business Overview
- 8.2.3 Zhihe Biotechnology Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)
- 8.2.4 Zhihe Biotechnology Radionuclide Drug Conjugate(RDC) Product Portfolio
- 8.2.5 Zhihe Biotechnology Recent Developments
- 8.3 Yuanda Pharmaceuticals
- 8.3.1 Yuanda Pharmaceuticals Comapny Information
- 8.3.2 Yuanda Pharmaceuticals Business Overview
- 8.3.3 Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)
- 8.3.4 Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
- 8.3.5 Yuanda Pharmaceuticals Recent Developments
- 8.4 Novartis
- 8.4.1 Novartis Comapny Information
- 8.4.2 Novartis Business Overview
- 8.4.3 Novartis Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)
- 8.4.4 Novartis Radionuclide Drug Conjugate(RDC) Product Portfolio
- 8.4.5 Novartis Recent Developments
- 8.5 Kelun Biotech
- 8.5.1 Kelun Biotech Comapny Information
- 8.5.2 Kelun Biotech Business Overview
- 8.5.3 Kelun Biotech Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)
- 8.5.4 Kelun Biotech Radionuclide Drug Conjugate(RDC) Product Portfolio
- 8.5.5 Kelun Biotech Recent Developments
- 8.6 Hengrui
- 8.6.1 Hengrui Comapny Information
- 8.6.2 Hengrui Business Overview
- 8.6.3 Hengrui Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)
- 8.6.4 Hengrui Radionuclide Drug Conjugate(RDC) Product Portfolio
- 8.6.5 Hengrui Recent Developments
- 8.7 Fulian Pharmaceuticals
- 8.7.1 Fulian Pharmaceuticals Comapny Information
- 8.7.2 Fulian Pharmaceuticals Business Overview
- 8.7.3 Fulian Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)
- 8.7.4 Fulian Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
- 8.7.5 Fulian Pharmaceuticals Recent Developments
- 8.8 Dongcheng Pharmaceuticals
- 8.8.1 Dongcheng Pharmaceuticals Comapny Information
- 8.8.2 Dongcheng Pharmaceuticals Business Overview
- 8.8.3 Dongcheng Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)
- 8.8.4 Dongcheng Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
- 8.8.5 Dongcheng Pharmaceuticals Recent Developments
- 8.9 Bayer
- 8.9.1 Bayer Comapny Information
- 8.9.2 Bayer Business Overview
- 8.9.3 Bayer Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)
- 8.9.4 Bayer Radionuclide Drug Conjugate(RDC) Product Portfolio
- 8.9.5 Bayer Recent Developments
- 8.10 Telix Pharmaceuticals
- 8.10.1 Telix Pharmaceuticals Comapny Information
- 8.10.2 Telix Pharmaceuticals Business Overview
- 8.10.3 Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)
- 8.10.4 Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
- 8.10.5 Telix Pharmaceuticals Recent Developments
- 8.11 Lantheus
- 8.11.1 Lantheus Comapny Information
- 8.11.2 Lantheus Business Overview
- 8.11.3 Lantheus Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)
- 8.11.4 Lantheus Radionuclide Drug Conjugate(RDC) Product Portfolio
- 8.11.5 Lantheus Recent Developments
- 8.12 Curium
- 8.12.1 Curium Comapny Information
- 8.12.2 Curium Business Overview
- 8.12.3 Curium Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)
- 8.12.4 Curium Radionuclide Drug Conjugate(RDC) Product Portfolio
- 8.12.5 Curium Recent Developments
- 9 Concluding Insights
- 10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.